Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
364.65%
-
Total 13F principal
-
$127,907,000
-
Principal change
-
-$53,209,000
-
Total reported market value
-
$453,455,000
-
Number of holders
-
12
-
Value change
-
-$195,070,770
-
Number of buys
-
2
-
Number of sells
-
5
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q3 2018
As of 30 Sep 2018,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 was held by
12 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$127,907,000
in principal (par value) of the bond.
The largest 10 bondholders included
Polygon Management Ltd., ANGELO GORDON & CO., L.P., CALAMOS ADVISORS LLC, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, LORD, ABBETT & CO. LLC, JPMORGAN CHASE & CO, Periscope Capital Inc., and MACKAY SHIELDS LLC.
This page lists
12
institutional bondholders reporting positions
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.